Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

41. Adults with acute asthma: can intravenous magnesium sulfate help?

Adults with acute asthma: can intravenous magnesium sulfate help? Adults with acute asthma: can intravenous magnesium sulfate help? - Evidently Cochrane Search and hit Go By May 30, 2014 // How useful is intravenous magnesium sulfate in treating people arriving in the Emergency Department with asthma attacks? Can it help some to avoid hospital admission? In this guest post, Dr Chris Cates looks at the latest evidence. The full report of the large “3Mg trial” of intravenous or nebulised (...) magnesium sulfate in adults with asthma exacerbations was published in April 2014[ ]. The authors concluded that they “were unable to demonstrate any clinically worthwhile benefit from magnesium sulphate in acute severe asthma”, and thereby questioned whether there was a place for using intravenous magnesium sulfate in adults with an asthma exacerbation who had not responded to the first line treatments of steroid tablets (on injections) in combination with nebulised salbutamol and ipratropium. However

2014 Evidently Cochrane

42. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. Full Text available with Trip Pro

School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. Antenatal magnesium sulfate given to pregnant women at imminent risk of very preterm delivery reduces the risk of cerebral palsy in early childhood, although its effects into school age have not been reported from randomized trials.To determine the association between exposure to antenatal magnesium sulfate and neurological, cognitive, academic, and behavioral outcomes at school age.The (...) ACTOMgSO4 was a randomized clinical trial conducted in 16 centers in Australia and New Zealand, comparing magnesium sulfate with placebo given to pregnant women (n = 535 magnesium; n = 527 placebo) for whom imminent birth was planned or expected before 30 weeks' gestation. Children who survived from the 14 centers who participated in the school-age follow-up (n = 443 magnesium; n = 424 placebo) were invited for an assessment at 6 to 11 years of age between 2005 and 2011.Mortality, cerebral palsy, motor

2014 JAMA Controlled trial quality: predicted high

43. Randomised controlled trial: The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores

Randomised controlled trial: The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings (...) via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The addition of nebulised magnesium

2014 Evidence-Based Medicine

44. Magnesium for alcohol withdrawal. (Abstract)

Magnesium for alcohol withdrawal. Patients have been given magnesium to treat or prevent alcohol withdrawal syndrome (AWS). Evidence to support this practice is limited, and is often based on the controversial link between hypomagnesaemia and AWS.To assess the effects of magnesium for the prevention or treatment of AWS in hospitalised adults.We searched the Cochrane Drugs and Alcohol Group Register of Controlled Trials (August 2012), PubMed (from 1966 to August 2012 ), EMBASE (from 1988 (...) to August 2012), CINAHL (from 1982 to March 2010), Web of Science (1965 to August 2012). We also carried out Internet searches.Randomised or quasi-randomised trials of magnesium for hospitalised adults with, or at risk for, acute alcohol withdrawal.Two review authors independently extracted data with a standardised data extraction form, contacting the correspondence investigator if the necessary information was not available in the reports. Dichotomous outcomes were analysed by calculating the risk

2013 Cochrane

45. Magnesium sulphate for women at term for neuroprotection of the fetus. Full Text available with Trip Pro

Magnesium sulphate for women at term for neuroprotection of the fetus. Magnesium sulphate is extensively used in obstetrics for the treatment and prevention of eclampsia. A recent meta-analysis has shown that magnesium sulphate is an effective fetal neuroprotective agent when given antenatally to women at risk of very preterm birth. Term infants account for more than half of all cases of cerebral palsy, and the incidence has remained fairly constant. It is important to assess if antenatal (...) administration of magnesium sulphate to women at term protects the fetus from brain injury, and associated neurosensory disabilities including cerebral palsy.To assess the effectiveness of magnesium sulphate given to women at term as a neuroprotective agent for the fetus.We searched the Cochrane Pregnancy and Childbirth Group's Trial Register (31 July 2012) and the reference lists of other Cochrane reviews assessing magnesium sulphate in pregnancy.Randomised controlled trials comparing antenatally

2013 Cochrane

46. Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials

Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

47. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate Pre Prev venting recurrent h enting recurrent hypomagnesaemia: or ypomagnesaemia: oral al magnesium gly magnesium glycerophosphate cerophosphate Evidence summary Published: 29 January 2013 nice.org.uk/guidance/esuom4 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national (...) formulary (BNF) or the MHRA or NICE websites for up-to-date information. Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. This evidence summary looks at the use of oral magnesium glycerophosphate

2013 National Institute for Health and Clinical Excellence - Advice

48. Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia

Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia Article Text

2013 Evidence-Based Mental Health

49. Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies

Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

50. Magnesium Laboratory Testing for Patients admitted for Heart Failure: Clinical Effectiveness and Guidelines

Magnesium Laboratory Testing for Patients admitted for Heart Failure: Clinical Effectiveness and Guidelines Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Magnesium Laboratory

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

51. Magnesium added to bupivacaine prolongs the duration of analgesia after interscalene nerve block Full Text available with Trip Pro

Magnesium added to bupivacaine prolongs the duration of analgesia after interscalene nerve block Local anesthetic adjuvants have been studied previously in an attempt to prolong the duration of analgesia after peripheral nerve blockade. Magnesium has been shown to have an antinociceptive effect in animal and human pain models. We evaluated the effects of adding magnesium sulphate to long-acting local anesthetics for interscalene nerve block to prolong the duration of analgesia and improve (...) the analgesic quality.We enrolled 66 patients undergoing arthroscopic rotator cuff repair. The interscalene nerve block was performed with 0.5% bupivacaine 20 mL with epinephrine (1:200,000) plus either 10% magnesium sulphate 2 mL (Magnesium Group) or normal saline 2 mL (Saline Group). The following data were recorded for 24 hr after surgery: onset times and durations of sensory and motor blocks, analgesic duration, the pain numeric rating scale (NRS), postoperative fentanyl consumption

2012 EvidenceUpdates Controlled trial quality: uncertain

52. Magnesium for Pre-Eclampia

Magnesium for Pre-Eclampia Magnesium for Pre-Eclampia – TheNNTTheNNT Magnesium Sulfate for Women with Preeclampsia 90 for seizure In Summary, for those who received the magneisum: Benefits in NNT For the mother: 98.8% saw no benefit 1.2% were helped by preventing a seizure For the child: 100% saw no benefit 0% were helped by avoiding mortality, NICU stay, preterm delivery For the mother: 1 in 90 were helped (seizure prevented) For the child: None were helped (death, NICU stay, avoiding preterm (...) maternal death). Although the mechanism is unclear magneisum sulfate has been used to prevent eclampsia since the 1950s. In this cochrane review, 11,444 women in 15 randomized trials were recruited from a mix of high, middle, and low income countries. The largest is the 33-country MagPie Trial comparing intravenous magnesium to placebo. The study was published in 2002 and at >10,000 subjects accounts for more than 87% of those in the review. The use of magnesium sulfate was associated with a greater

2012 theNNT

53. Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth. Full Text available with Trip Pro

Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth. The effectiveness of antenatal magnesium sulphate for neuroprotection of the fetus, infant, and child prior to very preterm birth, when given to women considered at risk of preterm birth, has been established. There is currently no consensus as to the regimen to use in terms of the dose, duration, the use of repeat dosing and timing.To assess the comparative effectiveness and adverse (...) effects of different magnesium sulphate regimens for neuroprotection of the fetus in women considered at risk of preterm birth.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 December 2011).Randomised trials comparing different magnesium sulphate regimens when used for neuroprotection of the fetus in women considered at risk of preterm birth. We planned to include cluster trials. We planned to exclude quasi-randomised trials and those with a crossover design. We planned

2012 Cochrane

54. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Full Text available with Trip Pro

Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Magnesium sulphate is a neuroprotective agent that might improve outcome after aneurysmal subarachnoid haemorrhage by reducing the occurrence or improving the outcome of delayed cerebral ischaemia. We did a trial to test whether magnesium therapy improves outcome after aneurysmal subarachnoid haemorrhage.We did this phase 3 randomised, placebo-controlled trial in eight centres in Europe and South (...) America. We randomly assigned (with computer-generated random numbers, with permuted blocks of four, stratified by centre) patients aged 18 years or older with an aneurysmal pattern of subarachnoid haemorrhage on brain imaging who were admitted to hospital within 4 days of haemorrhage, to receive intravenous magnesium sulphate, 64 mmol/day, or placebo. We excluded patients with renal failure or bodyweight lower than 50 kg. Patients, treating physicians, and investigators assessing outcomes

2012 Lancet Controlled trial quality: predicted high

55. Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy (Abstract)

Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy In a randomized, double-blind, prospective study, we investigated whether an intraoperative high versus low dose of remifentanil increased postoperative hyperalgesia and whether magnesium can prevent remifentanil-induced hyperalgesia.Ninety patients undergoing thyroidectomy were randomly assigned to 1 of 3 groups. Remifentanil was intraoperatively infused at 0.05 μg/kg/min (group LO

2011 EvidenceUpdates Controlled trial quality: predicted high

56. Magnesium-Essentials for Anesthesiologists Full Text available with Trip Pro

Magnesium-Essentials for Anesthesiologists Magnesium plays a fundamental role in many cellular functions, and thus there is increasing interest in its role in clinical medicine. Although numerous experimental studies indicate positive effects of magnesium in a variety of disease states, large clinical trials often give conflicting results. However, there is clear evidence for magnesium to benefit patients with eclampsia or torsades de pointes arrhythmias. In addition, magnesium seems to have (...) antinociceptive and anesthetic as well as neuroprotective effects, yet well-designed large clinical trials are required to determine its actual efficacy in pain management or in the state of stroke or subarachnoid hemorrhage. The current review aims to provide an overview of current knowledge and available evidence with respect to physiologic aspects of magnesium and proposed indications and recommendations for its use in the clinical setting.

2011 EvidenceUpdates

57. Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage

Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage BestBets: Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage Report By: Daniel Horner - ST4 Emergency Medicine / Critical Care Search checked by Craig Ferguson - SpR Emergency Medicine Institution: Manchester Royal Infirmary Date Submitted: 1st May (...) 2010 Date Completed: 27th January 2011 Last Modified: 27th January 2011 Status: Green (complete) Three Part Question In a patient presenting with [aneurysmal subarachnoid haemorrhage] does [early elevation of serum magnesium by administration of intravenous magnesium sulphate] lead to a reduction in [subsequent vasospasm incidence, morbidity or mortality rates] Clinical Scenario A 40 year old female attends the emergency department as a standby call. Her partner gives you a history of acute

2011 BestBETS

58. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial Full Text available with Trip Pro

The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial To determine whether nightly administration of melatonin, magnesium, and zinc improves primary insomnia in long-term care facility residents.Double-blind, placebo-controlled clinical trial.One long-term care facility in Pavia, Italy.Forty-three participants with primary insomnia (22 in the supplemented group, 21 in the placebo group (...) ) aged 78.3 ± 3.9.Participants took a food supplement (5 mg melatonin, 225 mg magnesium, and 11.25 mg zinc, mixed with 100 g of pear pulp) or placebo (100 g pear pulp) every day for 8 weeks, 1 hour before bedtime.The primary goal was to evaluate sleep quality using the Pittsburgh Sleep Quality Index. The Epworth Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire (LSEQ), the Short Insomnia Questionnaire (SDQ), and a validated quality-of-life instrument (Medical Outcomes Study 36-item Short

2011 EvidenceUpdates Controlled trial quality: predicted high

59. Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 Full Text available with Trip Pro

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 Cumulative sensory neurotoxicity (sNT) is the dose-limiting toxicity of oxaliplatin, which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant settings. In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT.Patients with colon cancer undergoing (...) adjuvant therapy with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were randomly assigned to Ca/Mg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo, in a double-blinded manner. The primary end point was the percentage of patients with grade 2 or greater sNT at any time during or after oxaliplatin-based therapy by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version 3) criteria. An oxaliplatin-specific sNT

2011 EvidenceUpdates Controlled trial quality: uncertain

60. Magnesium Sulphate for Fetal Neuroprotection Full Text available with Trip Pro

Magnesium Sulphate for Fetal Neuroprotection Magnesium Sulphate for Fetal Neuroprotection - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 33, Issue 5, Pages 516–529 Magnesium Sulphate for Fetal Neuroprotection PRINCIPAL AUTHORS, x Laura Magee , MD Vancouver BC x Diane Sawchuck , RN, PhD Vancouver BC x Anne Synnes , MD Vancouver BC x Peter von Dadelszen , MBChB Vancouver BC x THE MAGNESIUM SULPHATE FOR FETAL (...) as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective To provide guidelines for the use of antenatal magnesium sulphate (MgSO 4 ) for fetal neuroprotection of the preterm infant. Options Antenatal MgSO4 administration should be considered for fetal neuroprotection when women present at ≤ 31+6 weeks with imminent preterm birth, defined as a high likelihood of birth because of active labour with cervical dilatation ≥ 4 cm, with or without preterm pre-labour rupture

2011 Society of Obstetricians and Gynaecologists of Canada